{
    "clinical_study": {
        "@rank": "53499", 
        "acronym": "EVERBIOII", 
        "arm_group": [
            {
                "arm_group_label": "Everolimus-eluting bioresorbable vascular scaffold stents", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Everolimus-eluting stent", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Biolimus-eluting stent", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare the efficacy and safety of everolimus- and\n      biolimus-bluting stents with everolimus-eluting bioresorbable vascular scaffold stents.\n\n      The null hypothesis to be rejected is that there is no significant difference with regard to\n      lumen late loss at 9 months and a clinical end point of death, myocardial infarction and TVR\n      at 12 months between everolimus-eluting and biolimus-eluting stents and everolimus-eluting\n      bioresorbable vascular scaffold stents."
        }, 
        "brief_title": "Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Coronary Artery Disease", 
        "condition_browse": {
            "mesh_term": [
                "Coronary Artery Disease", 
                "Myocardial Ischemia", 
                "Coronary Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  elective PCI\n\n          -  ability and willingness to provide written informed consent\n\n        Exclusion Criteria:\n\n          -  ST-elevation myocardial infarction in the previous 48 hours\n\n          -  moderate to severe renal failure (defined as creatinine clearance of 30-60 ml/min and\n             <30ml/min respectively)\n\n          -  known or presumed hypersensitivity to heparin, antiplatelet drugs and\n             hypersensitivity to contrast dye incontrollable with premedication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 18, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01711931", 
            "org_study_id": "043/12-CER-FR"
        }, 
        "intervention": [
            {
                "arm_group_label": "Everolimus-eluting bioresorbable vascular scaffold stents", 
                "intervention_name": "Implantation of everolimus-eluting bioresorbable vascular scaffold stent", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Everolimus-eluting stent", 
                "intervention_name": "Implantation of everolimus-eluting stents", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "Biolimus-eluting stent", 
                "intervention_name": "Implantation of biolimus-eluting stents", 
                "intervention_type": "Device"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "percutaneous coronary intervention", 
            "bioresorbable vascular scaffold stents", 
            "everolimus", 
            "biolimus"
        ], 
        "lastchanged_date": "May 27, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Fribourg", 
                    "country": "Switzerland", 
                    "zip": "1708"
                }, 
                "name": "Fribourg Cantonal Hospital"
            }
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "3", 
        "official_title": "Comparison of Everolimus- and Biolimus-Eluting Stents With Everolimus-Eluting Bioresorbable Vascular Scaffold Stents", 
        "other_outcome": [
            {
                "description": "possible, probable and definite stent thrombosis", 
                "measure": "Stent thrombosis", 
                "safety_issue": "Yes", 
                "time_frame": "up to 5 years"
            }, 
            {
                "description": "Type 4A MI Dissection Perforation", 
                "measure": "Periprocedural Complications (occurring <48 hours after the Intervention)", 
                "safety_issue": "Yes", 
                "time_frame": "Periprocedural"
            }
        ], 
        "overall_official": [
            {
                "affiliation": "University of Freiburg", 
                "last_name": "St\u00e9phane Cook, Professor", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of Freiburg", 
                "last_name": "Mario Togni, Professor", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "University of Freiburg", 
                "last_name": "Serban Puricel, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Switzerland: Ethikkommission", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "as assessed by quantitative coronary angiogram", 
            "measure": "Lumen Late Loss", 
            "safety_issue": "No", 
            "time_frame": "9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01711931"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Freiburg", 
            "investigator_full_name": "St\u00e9phane Cook, Prof", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "results_reference": {
            "PMID": "24398143", 
            "citation": "Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, Villeneuve H, Boute E, Stauffer JC, Goy JJ, Cook S. Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial. Trials. 2014 Jan 7;15:9. doi: 10.1186/1745-6215-15-9."
        }, 
        "secondary_outcome": [
            {
                "description": "The composite of cardiac death, myocardial infarction (not clearly attributable to a nontarget vessel) and target lesion revascularization", 
                "measure": "Device-oriented major adverse cardiac events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months, 1, 2, 5 years"
            }, 
            {
                "description": "The composite of all-cause mortality, any myocardial infarction and any revascularization", 
                "measure": "Patient-oriented major adverse cardiac events", 
                "safety_issue": "Yes", 
                "time_frame": "6 months, 1, 2, 5 years"
            }
        ], 
        "source": "University of Freiburg", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Freiburg", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}